sacituzumab tirumotecan   Click here for help

GtoPdb Ligand ID: 13791

Synonyms: Jiataile® | MK-2870 | sac-TMT | SKB264
Approved drug
sacituzumab tirumotecan is an approved drug
Compound class: Antibody
Comment: Sacituzumab tirumotecan (SKB264/MK-2870) is an antibody-drug conjugate (ADC) [1]. It is the same humanized anti-TROP-2 monoclonal antibody as the previously approved ADC sacituzumab govitecan, but carrying a different topoisomerase inhibitor payload (tirumotecan/KL610023) that is a belotecan-derivative. TROP-2 is a transmembrane glycoprotein, cell surface antigen which has oncogenic activity in cancers of epithelial origin [2], but expression is restricted in normal tissue. Directing the topoisomerase inhibitor selectively to cancer cells via TROP-2 binding is predicted to limit toxicity towards healthy tissue/cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Sacituzumab tirumotecan (SKB264/MK-2870) was progressed as an oncology clinical candidate. The Chinese drug regulator (NMPA) approved sacituzumab tirumotecan (Jiataile®) in November 2024, to treat advanced triple-negative breast cancer. The FDA granted sacituzumab tirumotecan breakthrough designation in December 2024, making it available as an option for pretreated advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) harboring EGFR mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05347134 SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Phase 3 Interventional Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.